Literature DB >> 2105245

Prognostic value of the early serum estradiol response to leuprolide acetate in in vitro fertilization.

S L Padilla1, J Bayati, J E Garcia.   

Abstract

One hundred in vitro fertilization (IVF)-stimulated cycles were analyzed to evaluate the prognostic value of the early follicle-stimulating hormone (FSH), luteinizing hormone (LH), and estradiol (E2) response to the agonist action of leuprolide acetate. Four distinct early E2 response patterns were found. Pattern A (n = 41) showed a prompt elevation of E2, followed by a fall by cycle day 4. Pattern B (n = 16) showed a delayed elevation of E2, followed by a fall by cycle day 6. Pattern C (n = 19) showed a persistent elevation of E2. Pattern D (n = 18) lacked the early E2 response. The clinical pregnancy rates per cycle for patterns A, B, C, and D were 46%, 38%, 16%, and 6%, respectively. A baseline serum FSH level greater than 20 mIU/mL was associated with a lower clinical pregnancy rate, although not statistically significant. Baseline serum LH levels and stimulated FSH and LH levels did not predict IVF outcome. We conclude that the early E2 response pattern to leuprolide acetate is the best early prognostic indicator of IVF outcome.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2105245     DOI: 10.1016/s0015-0282(16)53283-x

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  11 in total

1.  Single and repeated GnRH agonist stimulation tests compared with basal markers of ovarian reserve in the prediction of outcome in IVF.

Authors:  D J Hendriks; F J Broekmans; L F J M M Bancsi; C W N Looman; F H de Jong; E R te Velde
Journal:  J Assist Reprod Genet       Date:  2005-02       Impact factor: 3.412

2.  High FSH:LH ratio and low LH levels in basal cycle day 3: impact on follicular development and IVF outcome.

Authors:  G Barroso; S Oehninger; A Monzó; P Kolm; W E Gibbons; S J Muasher
Journal:  J Assist Reprod Genet       Date:  2001-09       Impact factor: 3.412

3.  Cumulative exposure to high estradiol levels during the follicular phase of IVF cycles negatively affects implantation.

Authors:  Murat Arslan; Silvina Bocca; Ebru Ozturk Arslan; Hakan E Duran; Laurel Stadtmauer; Sergio Oehninger
Journal:  J Assist Reprod Genet       Date:  2007-02-16       Impact factor: 3.412

4.  Predicting pregnancy in women undergoing in-vitro fertilization with basal serum follicle stimulating hormone levels between 10.0 and 11.9 IU/L.

Authors:  Dan Levin; Sunny H Jun; Michael H Dahan
Journal:  J Turk Ger Gynecol Assoc       Date:  2015-03-01

5.  Ovarian activity during follicular-phase down regulation in in vitro fertilization is associated with advanced maternal age and a high recurrence rate in subsequent cycles.

Authors:  D R Session; A H Saad; D D Salmansohn; A C Kelly
Journal:  J Assist Reprod Genet       Date:  1995-05       Impact factor: 3.412

6.  The poor-responder patient in an in vitro fertilization-embryo transfer program.

Authors:  Z Ben-Rafael; D Feldberg
Journal:  J Assist Reprod Genet       Date:  1993-02       Impact factor: 3.412

7.  "Poor responders": screening and treatment possibilities.

Authors:  F Olivennes; R Fanchin; D De Ziegler; R Frydman
Journal:  J Assist Reprod Genet       Date:  1993-02       Impact factor: 3.412

8.  Preferred protocol: controlled ovarian stimulation.

Authors:  H W Jones
Journal:  J Assist Reprod Genet       Date:  1993-10       Impact factor: 3.412

9.  The antral follicle count predicts the outcome of pregnancy in a controlled ovarian hyperstimulation/intrauterine insemination program.

Authors:  M Y Chang; C H Chiang; T H Chiu; T T Hsieh; Y K Soong
Journal:  J Assist Reprod Genet       Date:  1998-01       Impact factor: 3.412

10.  Human intraovarian interleukin-1 (IL-1) system: highly compartmentalized and hormonally dependent regulation of the genes encoding IL-1, its receptor, and its receptor antagonist.

Authors:  A Hurwitz; J Loukides; E Ricciarelli; L Botero; E Katz; J M McAllister; J E Garcia; R Rohan; E Y Adashi; E R Hernandez
Journal:  J Clin Invest       Date:  1992-06       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.